Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tito Fojo

Showing results (71-80 of 237) with videos related to

Pageof 24
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2013
Tales of how great drugs were brought down by a flawed rationale--responseEdina Komlodi-Pasztor, Dan L Sackett, Tito Fojo
Nature Reviews. Cancer|March 21, 2002
Multidrug resistance in cancer: role of ATP-dependent transportersMichael M Gottesman, Tito Fojo, Susan E Bates
Cell Cycle (Georgetown, Tex.)|November 14, 2002
Inhibition of transcription results in accumulation of Wt p53 followed by delayed outburst of p53-inducible proteins: p53 as a sensor of transcriptional integrityMikhail V Blagosklonny, Zoya N Demidenko, Tito Fojo
Journal of the National Cancer Institute|November 3, 2011
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancerTito Fojo, Laleh Amiri-Kordestani, Susan E Bates
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2025
Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 InhibitorIan F Tannock, Qamar J Khan, Tito Fojo
Current Pharmaceutical Design|August 13, 2002
Epothilones: a novel class of non-taxane microtubule-stabilizing agentsRamin Altaha, Tito Fojo, Eddie Reed, et al.
International Journal of Cancer|May 7, 2002
Adenovirus HSV-TK construct with thyroid-specific promoter: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathwayMasaki Kitazono, Yutaka Chuman, Takashi Aikou, et al.
Nature Reviews. Clinical Oncology|December 20, 2017
The evidence framework for precision cancer medicineJeffrey A Moscow, Tito Fojo, Richard L Schilsky
FEBS Letters|April 7, 2005
Complementation of two mutant p53: implications for loss of heterozygosity in cancerZoya N Demidenko, Tito Fojo, Mikhail V Blagosklonny
Cell Cycle (Georgetown, Tex.)|September 14, 2006
Oligomerization of p53 precedes its association with dynein and nuclear accumulationShana Y Trostel, Dan L Sackett, Tito Fojo
Pageof 24

Showing results (71-80 of 237) with videos related to

Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2013
Tales of how great drugs were brought down by a flawed rationale--responseEdina Komlodi-Pasztor, Dan L Sackett, Tito Fojo
Nature Reviews. Cancer|March 21, 2002
Multidrug resistance in cancer: role of ATP-dependent transportersMichael M Gottesman, Tito Fojo, Susan E Bates
Cell Cycle (Georgetown, Tex.)|November 14, 2002
Inhibition of transcription results in accumulation of Wt p53 followed by delayed outburst of p53-inducible proteins: p53 as a sensor of transcriptional integrityMikhail V Blagosklonny, Zoya N Demidenko, Tito Fojo
Journal of the National Cancer Institute|November 3, 2011
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancerTito Fojo, Laleh Amiri-Kordestani, Susan E Bates
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2025
Why We Do Not Recommend That Women With Breast Cancer Receive Adjuvant Treatment With a CDK4/6 InhibitorIan F Tannock, Qamar J Khan, Tito Fojo
Current Pharmaceutical Design|August 13, 2002
Epothilones: a novel class of non-taxane microtubule-stabilizing agentsRamin Altaha, Tito Fojo, Eddie Reed, et al.
International Journal of Cancer|May 7, 2002
Adenovirus HSV-TK construct with thyroid-specific promoter: enhancement of activity and specificity with histone deacetylase inhibitors and agents modulating the camp pathwayMasaki Kitazono, Yutaka Chuman, Takashi Aikou, et al.
Nature Reviews. Clinical Oncology|December 20, 2017
The evidence framework for precision cancer medicineJeffrey A Moscow, Tito Fojo, Richard L Schilsky
FEBS Letters|April 7, 2005
Complementation of two mutant p53: implications for loss of heterozygosity in cancerZoya N Demidenko, Tito Fojo, Mikhail V Blagosklonny
Cell Cycle (Georgetown, Tex.)|September 14, 2006
Oligomerization of p53 precedes its association with dynein and nuclear accumulationShana Y Trostel, Dan L Sackett, Tito Fojo
Pageof 24